Form 4: 4D Molecular Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
David Kirn, See Remarks and a Director of 4D Molecular Therapeutics, Inc., sold 58,333 shares of common stock on July 9, 2026.
Summary
- Open-market sale: disposed of 42,608 Common Stock at $12.87 ($548,177) on July 9, 2026; holds 899,877 after (Direct).
- Open-market sale: disposed of 15,283 Common Stock at $12.01 ($183,560) on July 10, 2026; holds 884,594 after (Direct).
- Open-market sale: disposed of 442 Common Stock at $12.84 ($5,673) on July 10, 2026; holds 884,152 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $737,410 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
David Kirn — Director, Officer (See Remarks)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-09 | Open-market sale | Common Stock | 42,608 | $13 | $548.2K | 899,877 |
| 2026-07-10 | Open-market sale | Common Stock | 15,283 | $12 | $183.6K | 884,594 |
| 2026-07-10 | Open-market sale | Common Stock | 442 | $13 | $5.7K | 884,152 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-09 | Open-market sale (42,608 shares) |
| 2026-07-10 | Open-market sale (15,283 shares) |
| 2026-07-10 | Open-market sale (442 shares) |
Keywords
insider transaction, Form 4, FDMT, 4D Molecular Therapeutics, Inc., bearish, David Kirn
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.